东诚药业：公司为中硼联康的参股股东，公司为其BNCT药物BPA承担药学研究部分的相关工作

Group 1 - The company is a shareholder in Zhongborun Kang Medical and is responsible for the pharmaceutical research related to its BNCT drug BPA [1] - There is no collaboration between the company and TAE Life Sciences, a subsidiary of TAE Technologies in the United States [1]